Fig. 7: Pharmacological inhibition of NNMT overcomes EGFR-TKIs resistance in NSCLC cells in vivo. | Cell Death Discovery

Fig. 7: Pharmacological inhibition of NNMT overcomes EGFR-TKIs resistance in NSCLC cells in vivo.

From: Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells

Fig. 7: Pharmacological inhibition of NNMT overcomes EGFR-TKIs resistance in NSCLC cells in vivo.

A–C 5 × 106 PC9/GR cells were subcutaneously injected into nude mice and palpable tumors were allowed to develop for 7 days. Mice were randomly divided into four groups and treated with vehicle control (0.01% DMSO in PBS), gefitinib (50 mg/kg/d), JBSNF-000088 (50 mg/kg/d), or a combination of gefitinib with JBSNF-000088 every other day (n = 4, per group), A The tumor size was measured at indicated time intervals and calculated. The tumor volume was calculated using the formula: V = 1/2 × larger diameter × (smaller diameter)2, and growth curves were plotted using average tumor volume within each experimental group at the set time points, B At the end of treatment, tumors were excised, C Tumor weights were measured. D Treatment of gefitinib or/and JBSNF-000088 has no effect on mouse body weight. E PC9/GR xenograft tissues derived from mice were fixed, sectioned, and placed on slides. Tumor specimens were subjected to immunohistochemical staining with antibodies specific to SIRT and c-myc. (**p < 0.01).

Back to article page